T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.41% |
| 4 | Industrials | 12.4% |
| 5 | Technology | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
CNX Resources
CNX
$5.35B
| $817M | 0.17% |
28,992,472
+1,798,942
| +7% | +$54.6M |
|
|
N
152
DELISTED
Netsuite Inc
N
| $815M | 0.17% |
7,460,849
-990,863
| -12% | -$101M |
|
153
IBM
IBM
$225B
| $811M | 0.17% |
5,287,785
+1,168,713
| +28% | +$186M |
|
|
CXO
154
DELISTED
CONCHO RESOURCES INC.
CXO
| $804M | 0.17% |
8,057,420
-4,597,083
| -36% | -$482M |
|
155
SLB Ltd
SLB
$79.7B
| $793M | 0.17% |
9,288,470
-1,735,178
| -16% | -$160M |
|
156
HCA Healthcare
HCA
$89.1B
| $781M | 0.17% |
10,644,405
+2,411,206
| +29% | +$169M |
|
157
Mattel
MAT
$4.29B
| $775M | 0.16% |
25,051,158
+5,822,960
| +30% | +$179M |
|
158
IDEX
IEX
$17.5B
| $772M | 0.16% |
9,913,639
+2,164,059
| +28% | +$161M |
|
159
Bath & Body Works
BBWI
$3.81B
| $771M | 0.16% |
11,022,284
-151,814
| -1% | -$9.37M |
|
160
Ameriprise Financial
AMP
$49.7B
| $769M | 0.16% |
5,811,896
-238,463
| -4% | -$30.2M |
|
161
Dentsply Sirona
XRAY
$2.31B
| $762M | 0.16% |
14,307,152
-1,609,207
| -10% | -$81.9M |
|
162
Motorola Solutions
MSI
$77.3B
| $759M | 0.16% |
11,315,327
+1,918,040
| +20% | +$122M |
|
163
Duke Energy
DUK
$96.1B
| $754M | 0.16% |
9,022,743
-1,232,746
| -12% | -$99.4M |
|
164
Invesco
IVZ
$13.8B
| $750M | 0.16% |
18,976,385
-10,128,894
| -35% | -$399M |
|
165
Zoetis
ZTS
$31.1B
| $750M | 0.16% |
17,421,954
-5,508,369
| -24% | -$224M |
|
166
Sysco
SYY
$40.3B
| $747M | 0.16% |
18,824,606
+1,227,448
| +7% | +$47.6M |
|
|
167
Ashland
ASH
$3.42B
| $744M | 0.16% |
12,700,621
+12,406,009
| +4,211% | +$669M |
|
|
BNY
168
Bank of New York Mellon
BNY
$109B
| $743M | 0.16% |
18,307,949
+8,069,338
| +79% | +$316M |
|
|
IHS
169
DELISTED
IHS INC CL-A COM STK
IHS
| $741M | 0.16% |
6,506,218
-408,983
| -6% | -$50.8M |
|
170
Flowserve
FLS
$10.3B
| $736M | 0.16% |
12,305,030
+4,882,697
| +66% | +$311M |
|
171
Amgen
AMGN
$224B
| $736M | 0.16% |
4,617,881
-178,988
| -4% | -$27.9M |
|
172
Archer Daniels Midland
ADM
$38.8B
| $732M | 0.16% |
14,072,209
-3,157,791
| -18% | -$157M |
|
173
Hilton Worldwide
HLT
$70.8B
| $724M | 0.15% |
9,245,685
+613,406
| +7% | +$46M |
|
174
ASML
ASML
$691B
| $700M | 0.15% |
6,494,703
-3,246,107
| -33% | -$329M |
|
|
TFCFA
175
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $700M | 0.15% |
18,214,436
-2,297,784
| -11% | -$81.3M |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.